Shares of cancer drug developer Erasca plunge 55% after a patient dies from drug side effects

Glonghui April 29｜The stock price of a certain exchange plummeted by 55%, marking its largest single-day drop since its IPO in 2021. Previously, the company stated that a patient withdrew from a clinical trial and later died due to severe treatment-related side effects. The San Diego-based company disclosed this information while releasing early-stage clinical trial data for its experimental therapies targeting pancreatic and lung cancer. The company stated that the therapy was generally well tolerated, with most side effects being of a low grade.